Acuta Capital Partners LLC Purchases Shares of 21,000 Ascendis Pharma A/S (NASDAQ:ASND)

Acuta Capital Partners LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 21,000 shares of the biotechnology company's stock, valued at approximately $3,136,000. Ascendis Pharma A/S accounts for 2.5% of Acuta Capital Partners LLC's investment portfolio, making the stock its 17th largest holding.

Several other institutional investors and hedge funds have also recently bought and sold shares of ASND. Loomis Sayles & Co. L P raised its holdings in Ascendis Pharma A/S by 35.3% in the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company's stock valued at $27,566,000 after acquiring an additional 48,120 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Ascendis Pharma A/S by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company's stock worth $1,664,000 after purchasing an additional 4,338 shares during the last quarter. Evolutionary Tree Capital Management LLC grew its stake in shares of Ascendis Pharma A/S by 82.3% during the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company's stock worth $3,391,000 after purchasing an additional 11,223 shares in the last quarter. SG Americas Securities LLC increased its holdings in Ascendis Pharma A/S by 221.0% in the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company's stock valued at $833,000 after buying an additional 4,205 shares during the last quarter. Finally, First Turn Management LLC lifted its holdings in Ascendis Pharma A/S by 23.1% during the 2nd quarter. First Turn Management LLC now owns 186,581 shares of the biotechnology company's stock worth $25,446,000 after buying an additional 34,994 shares during the last quarter.

Analyst Ratings Changes

ASND has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a report on Wednesday, October 23rd. Cantor Fitzgerald restated an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Wedbush reiterated an "outperform" rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. TD Cowen lowered their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. Finally, StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of "Moderate Buy" and an average price target of $191.77.

Ascendis Pharma A/S Trading Up 1.3 %

Shares of NASDAQ:ASND traded up $1.72 on Thursday, reaching $136.32. 355,486 shares of the company were exchanged, compared to its average volume of 451,773. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The firm has a market cap of $8.27 billion, a price-to-earnings ratio of -16.87 and a beta of 0.66. The company has a 50-day moving average of $132.55 and a 200-day moving average of $132.21.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, analysts forecast that Ascendis Pharma A/S will post -7.45 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.